Protalix Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Protalix Biotherapeutics
PLX Stock  USD 1.75  0.03  1.74%   
Protalix Biotherapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Protalix Biotherapeutics' valuation are provided below:
Gross Profit
35.6 M
Profit Margin
0.0872
Market Capitalization
139.1 M
Enterprise Value Revenue
1.8941
Revenue
61.8 M
We have found one hundred twenty available trending fundamental ratios for Protalix Biotherapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Protalix Biotherapeutics recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 1.2 B in 2025, whereas Market Cap is likely to drop slightly above 72.5 M in 2025.

Protalix Biotherapeutics Total Revenue

56.07 Million

Check Protalix Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protalix Biotherapeutics' main balance sheet or income statement drivers, such as Interest Expense of 1 M, Selling General Administrative of 42.8 M or Other Operating Expenses of 32.3 M, as well as many indicators such as Price To Sales Ratio of 2.43, Dividend Yield of 0.0 or PTB Ratio of 3.0. Protalix financial statements analysis is a perfect complement when working with Protalix Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Protalix Stock
Check out the analysis of Protalix Biotherapeutics Correlation against competitors.
For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.

Protalix Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets52.1 M73.4 M68.5 M
Very volatile
Total Current Liabilities20.5 M25.6 M31.7 M
Slightly volatile
Cash31.4 M19.8 M38.5 M
Slightly volatile
Non Current Assets Total9.8 M13.3 M11.9 M
Very volatile
Cash And Short Term Investments33.8 M34.8 M42.5 M
Pretty Stable
Net Receivables2.9 M2.9 M2.9 M
Slightly volatile
Common Stock Shares Outstanding85.1 M81.1 M29.3 M
Slightly volatile
Liabilities And Stockholders Equity52.1 M73.4 M68.5 M
Very volatile
Non Current Liabilities Total4.4 M4.6 M49.6 M
Slightly volatile
Other Current Assets1.6 M1.1 M2.2 M
Slightly volatile
Total Liabilities55.3 M30.2 M83.2 M
Pretty Stable
Total Current Assets43.3 M60.1 M56.6 M
Very volatile
Short and Long Term Debt Total5.2 M5.5 M47.5 M
Slightly volatile
Property Plant And Equipment Net10.5 M10 M10.3 M
Pretty Stable
Non Currrent Assets Other438.9 K462 K2.5 M
Slightly volatile
Common Stock Total Equity62.7 K40.2 K71.3 K
Slightly volatile
Other Stockholder Equity442.6 M421.5 M300.2 M
Slightly volatile
Common Stock63.6 K76 K77.8 K
Pretty Stable
Accounts Payable4.1 M4.5 M5.5 M
Very volatile
Short Term Investments15.8 M15.1 M7.5 M
Slightly volatile
Other Assets3.5 M3.3 M1.6 M
Slightly volatile
Other Liabilities1.4 M1.5 M19.8 M
Slightly volatile
Property Plant Equipment8.2 M10 M9.9 M
Pretty Stable
Current Deferred Revenue3.1 M3.3 M7.9 M
Very volatile
Inventory22.3 M21.2 M10.4 M
Slightly volatile
Capital Surpluse298.9 M421.5 M265.5 M
Slightly volatile
Non Current Liabilities Other43.6 K45.9 K30.1 M
Slightly volatile
Short and Long Term Debt34.9 M18.2 M40.5 M
Slightly volatile
Deferred Long Term Asset Charges101.6 K101.7 K118.6 K
Slightly volatile
Property Plant And Equipment Gross23.1 M45.8 M18.9 M
Slightly volatile
Cash And Equivalents22.5 M19.8 M37.8 M
Slightly volatile
Capital Stock51.1 K76 K105.1 K
Slightly volatile
Capital Lease Obligations4.5 M5.5 M5.6 M
Slightly volatile

Protalix Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Operating Expenses32.3 M49.5 M45.8 M
Slightly volatile
Total Operating Expenses25 M25.2 M34.8 M
Pretty Stable
Depreciation And Amortization1.6 M1.3 M2 M
Slightly volatile
Total Revenue56.1 M53.4 M32.8 M
Slightly volatile
Gross Profit15 M29.1 M19.3 M
Slightly volatile
Cost Of Revenue25.5 M24.3 M12.2 M
Slightly volatile
Research Development12.3 M13 M26 M
Very volatile
Selling And Marketing Expenses55.6 M53 M18.6 M
Slightly volatile
Extraordinary Items29.6 K33.3 K36.3 K
Slightly volatile
Interest Income768.8 K1.3 M662 K
Slightly volatile
Reconciled Depreciation1.1 M1.3 M1.6 M
Slightly volatile

Protalix Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow30.8 M23.6 M39.5 M
Pretty Stable
End Period Cash Flow31.4 M19.8 M38.5 M
Slightly volatile
Depreciation2 M1.3 M2 M
Slightly volatile
Stock Based Compensation2.3 M3.3 M2.4 M
Pretty Stable
Issuance Of Capital Stock3.4 M3.6 M37.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.432.553677.3141
Slightly volatile
Days Sales Outstanding18.8919.88434.4501
Slightly volatile
Average Payables45.2 K47.6 K49.7 K
Slightly volatile
Stock Based Compensation To Revenue0.05790.06091.5293
Slightly volatile
Capex To Depreciation1.210.98310.6925
Pretty Stable
EV To Sales2.172.28777.0918
Slightly volatile
Inventory Turnover1.81.14481.6476
Slightly volatile
Days Of Inventory On Hand501319458
Very volatile
Payables Turnover5.635.36492.795
Slightly volatile
Research And Ddevelopement To Revenue0.230.24292.8847
Slightly volatile
Capex To Revenue0.02280.0240.086
Slightly volatile
Cash Per Share0.460.48021.529
Slightly volatile
Days Payables Outstanding64.6368.0351331
Slightly volatile
Current Ratio2.232.34497.8966
Slightly volatile
Receivables Turnover19.2718.356513.2494
Slightly volatile
Graham Number1.170.73611.1767
Slightly volatile
Capex Per Share0.01680.01770.0579
Slightly volatile
Revenue Per Share0.70.73622.2474
Slightly volatile
Interest Debt Per Share0.08630.09081.3351
Very volatile
Debt To Assets0.07150.07530.6037
Pretty Stable
Operating Cycle322339473
Very volatile
Days Of Payables Outstanding64.6368.0351331
Slightly volatile
Quick Ratio1.441.51577.556
Slightly volatile
Cash Ratio0.730.77122.1385
Slightly volatile
Days Of Inventory Outstanding501319458
Very volatile
Days Of Sales Outstanding18.8919.88434.4501
Slightly volatile
Fixed Asset Turnover5.65.32873.7955
Slightly volatile
Debt Ratio0.07150.07530.6037
Pretty Stable
Price Sales Ratio2.432.553677.3141
Slightly volatile
Asset Turnover0.590.72730.574
Pretty Stable
Gross Profit Margin0.570.54460.5351
Slightly volatile

Protalix Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap72.5 M76.4 M684.8 M
Slightly volatile
Enterprise Value1.2 B867.5 M1.3 B
Slightly volatile

Protalix Fundamental Market Drivers

Forward Price Earnings9.8328
Cash And Short Term Investments34.8 M

Protalix Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Protalix Biotherapeutics Financial Statements

Protalix Biotherapeutics investors use historical fundamental indicators, such as Protalix Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protalix Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.3 M3.1 M
Total Revenue53.4 M56.1 M
Cost Of Revenue24.3 M25.5 M
Stock Based Compensation To Revenue 0.06  0.06 
Sales General And Administrative To Revenue(0.33)(0.31)
Research And Ddevelopement To Revenue 0.24  0.23 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.74  0.70 
Ebit Per Revenue 0.07  0.08 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
CCitigroup
CRMSalesforce

Additional Tools for Protalix Stock Analysis

When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY